MENU

AustralianSuper rejects better Healthscope Ltd offer

The drama continues with the potential takeover of private hospital operator Healthscope Ltd (ASX: HSO).

AustralianSuper is part of a bidding consortium, along with BGH Capital and a few Canadian pension funds, which put in the initial bid for Healthscope a few weeks ago at $2.36 per share. However, at the time AustralianSuper said it would vote down any other offers – it is already a substantial shareholder. In total the group owns around 14.5% of the shares.

Yesterday, an offer came in for Healthscope at $2.50 from Brookfield, a global real estate manager. This offer is clearly superior to the first for most of Healthscope’s current shareholders.

The problem is that AustralianSuper doesn’t want to sell its shares, it wants to increase its holding of Healthscope. So it wants as low of a price as possible to pay for the new shares it wants to buy.

AustralianSuper is going to reject the Brookfield offer according to the Australian Financial Review.

However, that doesn’t mean the offer will be rejected by Healthscope. The consortium only owns 14.5% of the shares, it’s in the interest of the rest of the shareholders to accept the better offer. Therefore the other shareholders likely have the numbers to accept the Brookfield offer.

Foolish takeaway

I’m not sure who’s going to be the eventual owner of Healthscope, but it appears that both sides aren’t going to offer any more. Brookfield is offering the best deal and AustralianSuper doesn’t want to pay more than its first offer. As I said yesterday in my article, for current shareholders it would probably be best to sell on the market and move on – a price of $2.58 yesterday was more than the best offer price.

I’d want to put my Healthscope money into one of these top shares which are all growing impressively.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!